Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Vitamin D May Help Unclog Amyloid Plaques in Alzheimer’s Patients

By BiotechDaily International staff writers
Posted on 21 Mar 2012
Scientists have identified the intracellular mechanisms regulated by vitamin D3 that may help the body clear the brain of amyloid beta, the chief component of plaques tied to Alzheimer’s disease (AD).

Published in the March 6, 2012, issue of the Journal of Alzheimer’s Disease, the preliminary findings revealed that vitamin D3 may trigger key genes and cellular signaling networks to help stimulate the immune system to clear the amyloid-beta protein. Earlier laboratory research conducted by the team demonstrated that specific types of immune cells in Alzheimer’s patients may respond to therapy with vitamin D3 and curcumin, a chemical found in turmeric spice, by triggering the innate immune system to clear amyloid beta. However, the researchers could not determine how exactly it worked.

“This new study helped clarify the key mechanisms involved, which will help us better understand the usefulness of vitamin D3 and curcumin as possible therapies for Alzheimer’s disease,” said study author Dr. Milan Fiala, a researcher at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and the Veterans Affairs Greater Los Angeles Healthcare System.

For the study, scientists drew blood samples from AD patients and healthy controls and then isolated critical immune cells from the blood called macrophages, which are responsible for gobbling up amyloid beta and other waste products in the brain and body.

The investigators incubated the immune cells overnight with amyloid beta. An active form of vitamin D3 called 1a,25-dihydroxyvitamin D3, which is produced the body by enzymatic conversion in the liver and kidneys, was added to some of the cells to evaluate the effect it had on amyloid beta absorption.

Earlier research by the team, based on the function of AD patients’macrophages, demonstrated that there are at least two types of patients and macrophages: type I macrophages are improved by addition of 1a,25-dihydroxyvitamin D3 and curcuminoids, whereas type II macrophages are enhancedonly by adding 1a,25-dihydroxyvitamin D3.

Researchers found that in both type I and II macrophages, the added 1a,25-dihydroxyvitamin D3 played a major role in opening a specific chloride channel called chloride channel 3 (CLC3), which is vital in supporting the uptake of amyloid beta through the process known as phagocytosis. Curcuminoids activated this chloride channel only in type I macrophages.

The scientists also discovered that 1a,25-dihydroxyvitamin D3 strongly helped trigger the genetic transcription of the chloride channel and the receptor for 1a,25-dihydroxyvitamin D3 in type II macrophages. Transcription is the first step leading to gene expression. The processes underlying the effects of 1a,25-dihydroxyvitamin D3 on phagocytosis were complex and dependent on calcium and signaling by the MAPK pathway, which helps communicate a signal from the vitamin D3 receptor located on the surface of a cell to the DNA in the cell’s nucleus.

The essential effect of 1a,25-dihydroxyvitamin D3 was shown in a collaboration between Dr. Patrick R. , from the Scripps Research Institute (La Jolla, CA, USA), and Dr. Mathew T. Mizwicki, from the University of California (UC), Riverside (USA). They utilized a technique based on mass spectrometry, which showed that 1a,25-dihydroxyvitamin D3 stabilized many more key sites on the vitamin D receptor than did the curcuminoids.

“Our findings demonstrate that active forms of vitamin D3 may be an important regulator of immune activities of macrophages in helping to clear amyloid plaques by directly regulating the expression of genes, as well as the structural physical workings of the cells,” said study author Mizwicki, who was an assistant research biochemist in the department of biochemistry at UC Riverside when the study was conducted.

According to the investigators, one of the next phases of research would be a clinical trial with vitamin D3 to evaluate the impact on AD patients. Previous studies by other teams have shown that a low serum level of 25-hydroxyvitamin D3 may be associated with cognitive decline. It is too early to recommend a standard dosage of vitamin D3 to help with AD and brain health, according to the researchers.

Related Links:
David Geffen School of Medicine at the University of California, Los Angeles
Scripps Research Institute
University of California, Riverside


Channels

Genomics/Proteomics

view channel
Image: The osteochondroretricular stem cell is a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis, osteoporosis, and bone fractures. In this illustration of the head of a femur, osteochondroretricular stem cells are visualized in red (Photo courtesy of Dr. Timothy Wang, Columbia University).

Gremlin 1 Expression Distinguishes Stem Cells Able to Regenerate Bones and Cartilage in Adult Mice

A newly identified type of stem cell in the bone marrow of adult mice was found to be capable of regenerating both bone and cartilage. Investigators at Columbia University (New York, NY, USA) reported... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.